Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Combined With Taxane Neoadjuvant Therapy for HER2-positive Breast Carcinoma in Situ
NCT06843681Phase 2Enrolling by invitation
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in Breast carcinoma in situ (BCIS), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Breast-conserving surgery rate. Started Mar 2025; status: enrolling by invitation.
02
Drugs
03
Conditions
Breast carcinoma in situ (BCIS)
Beyond the preview
Go deeper on NCT06843681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06843681.